- Erlotinib, sold
under the
brand name
Tarceva among others, is a
medication used to
treat non-small cell lung
cancer (NSCLC) and
pancreatic cancer. Specifically...
-
inhibitor intellectual property.
Tarceva (Erlotinib) was OSI's
flagship and, as of 2007, only
marketed product.
Tarceva is a
small molecule inhibitor of...
-
breast cancer treatment was
subsequently revoked in
November 2011. 2004:
Tarceva (erlotinib):
Treatment for
patients with
locally advanced or metastatic...
-
gives him a bit of
relief because it
means that he can be
treated with
Tarceva,
which typically results in less-severe side
effects compared to traditional...
- (oseltamivir), for
influenza A and B (both
treatment and prevention).
Tarceva (erlotinib), for
various cancers.
Tasmar (tolcapone), for parkinson's disease...
-
Actemra launched 2007:
Copegus , an antiviral,
Avastin , a
cancer drug, and
Tarceva , a
cancer drug
launched 2011 –
Produced Actemra, a
human IL-6 receptor...
-
approved in the U.S. for non
small cell lung cancer.
Erlotinib (marketed as
Tarceva).
Erlotinib inhibits epidermal growth factor receptor, and
works through...
-
dermatitis (eczema)
Symoron (methadone HCL) –
Opioid replacement therapy Tarceva (erlotinib) – Non-small cell lung
cancer and
pancreatic cancer – marketed...
- nifedipine,
nisoldipine (Sular) and
nitrendipine (Bayotensin)
Erlotinib (
Tarceva) Exemestane, aromasin, and by
extension all estrogen-like
compounds and...
- 2001
Gefitinib (Iressa) EGFR
Esophageal cancer,
Glioma 2003
Erlotinib (
Tarceva) EGFR
Esophageal cancer,
Glioma 2004
Sorafenib (Nexavar) Raf, VEGFR, PDGFR...
